Comparison of adc metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab

HIGHLIGHTS

• who: Newly diagnosed GBM ADC and collaborators from the Department of Radiology and Biomedical Imaging, University Hall, Box, San Francisco, CA, USA have published the paper: Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab, in the Journal: (JOURNAL)
• what: The aim of this study was to evaluate the association of ADC metrics with clinical outcomes for patients with newly diagnosed GBM who were participating in a Phase II clinical trial that included bevacizumab. The fDM analysis was developed to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.